We separate the science from the misinformation. Every myth examined against verifiable evidence.
No. Research peptides are legal in Mexico. They are not controlled substances and require no prescription when acquired for research purposes.
Research peptides are not classified as controlled substances in Mexico. They are sold under the "For Professional Clinical Use" label.
No. Peptides are short amino-acid chains, entirely different from anabolic steroids, which are hormone derivatives. Their mechanisms of action are distinct.
Peptides act as cellular signaling molecules, while steroids modulate androgen receptors. They are chemically incomparable.
Absolutely not. Purity varies enormously between suppliers. A peptide at 80% purity carries 20% impurities that can be toxic. Only suppliers with ≥99% HPLC purity and a verifiable COA can guarantee quality.
HPLC chromatography is the gold standard for verifying purity. EXOMA Peptides includes a COA with every product, verifiable online.
See more ›Research peptides generally show favorable safety profiles in available studies. Side effects tend to be mild: injection-site redness, temporary nausea or headache.
BPC-157 has 100+ preclinical studies with no reports of significant toxicity. PT-141 has FDA approval (Vyleesi®). GH secretagogues like Ipamorelin are well tolerated in clinical studies.
No. Research peptides create no physical or psychological dependence. Unlike opioids or benzodiazepines, they do not act on reward receptors or produce tolerance.
Neither DSIP (sleep), nor Semax/Selank (cognitive), nor BPC-157 (regeneration) show dependence patterns in the literature.
For research peptides (For Professional Clinical Use), no prescription is required in Mexico. These materials are exclusively for scientific research.
Research peptides are sold as laboratory reagents, not medicines. EXOMA Peptides recommends specialized guidance for any research protocol.
No. Peptides have decades of research behind them. BPC-157 has been studied since the 1990s, Epithalon since the 1980s (Prof. Khavinson), and several have regulatory approvals (Tesamorelin FDA, PT-141 FDA).
PubMed lists thousands of publications on therapeutic peptides. The global peptide market exceeds $40 billion USD and grows 7-8% annually.
At EXOMA Peptides, every product includes a verifiable COA, high HPLC-certified purity, and expert support.
